News

September 28, 2017 - ViaCyte Awarded New CIRM Grant to Support Clinical Trial of PEC-Direct Product Candidate for High Risk Type 1 Diabetes Read More

September 21, 2017 - ViaCyte Selected as a Finalist for CONNECT’s 30th Annual Most Innovative New Product Awards Read More

September 14, 2017 - CONNECT Announces Finalists for 2017 Most Innovative New Products Awards Read More

September 11, 2017 - SpecificiT Raises Seed Financing Read More

September 7, 2017 - ViaCyte to Present at Upcoming Scientific Meetings on Diabetes Research Read More

August 28, 2017 - DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial — Dalcetrapib Studied in Genetically Targeted Patients with Acute Coronary Syndrome — Read More

August 1, 2017 - ViaCyte Announces First Patients Implanted with PEC-Direct Islet Cell Replacement Therapy in International Clinical Trial Read More

July 27, 2017 - PreciThera Inc. Completes $36 Million Series A Financing: Funding to Develop Novel Biologics Targeting Orphan Bone Diseases into Clinical Trials Read More

June 15, 2017 - ViaCyte Presents at the ISSCR 2017 Annual Meeting in Boston Read More

June 1, 2017 - Can DalCor Pharma Succeed Where Others Have Failed? Read More